

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
MANT-A Internal request Reassess the category for zanubrutinib as a second-line therapy for patients with mantle cell lymphoma who have received at least one prior therapy and have an extended response duration to prior chemoimmunotherapy (> expected median PFS).	The panel reassessed the recommendation for zanubrutinib as a second-line therapy for patients with mantle cell lymphoma who have received at least one prior therapy and have an extended response duration to prior chemoimmunotherapy (> expected median PFS). The panel consensus resulted in a change from a category 2B to a category 2A recommendation in order to maintain consistency with the category for short response duration to prior chemoimmunotherapy (< expected median PFS).	22	1	2	4